Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6844305 | 0.87 | ALDH1A1 (0.33) | ALDH1A1TDP1MEN1CYP1A2THRB | |
| SCHEMBL137424 | 0.81 | ALDH1A1 (0.41) | ALDH1A1TSHRTDP1HSD17B10LMNA | |
| SCHEMBL6844307 | 0.76 | ALDH1A1 (0.56) | ALDH1A1TSHRLMNAMEN1CYP1A2 | |
| SCHEMBL1728131 | 0.75 | ALDH1A1 (0.45) | ALDH1A1TSHRTDP1HSD17B10LMNA | |
| SCHEMBL4957127 | 0.75 | — | — | |
| SCHEMBL27991129 | 0.75 | — | — | |
| SCHEMBL29116160 | 0.74 | ALDH1A1 (0.38) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL29116162 | 0.74 | — | — | |
| SCHEMBL1417855 | 0.73 | ALDH1A1 (0.43) | ALDH1A1TSHRTDP1HSD17B10LMNA | |
| SCHEMBL4653162 | 0.73 | ALDH1A1 (0.43) | ALDH1A1TSHRTDP1HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970511-B1 | INSULIN-INCRETIN CONJUGATES | UNIV INDIANA RES & TECH CORP (US) | 2020-09-30 | — | — | EP | disclosed |
| US-10730923-B2 | Glucagon/GLP-1 receptor co-agonists | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-08-04 | — | — | US | disclosed |
| US-10696726-B2 | Insulin-incretin conjugates | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-10683334-B2 | Aqueously soluble and chemically stable glucagon peptides | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-06-16 | — | — | US | disclosed |
| EP-3206710-B1 | INCRETIN-INSULIN CONJUGATES | UNIV INDIANA RES & TECH CORP (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20190290772-A1 | GLUCAGON-LIKE PEPTIDE-1-T3 CONJUGATES | UNIV INDIANA RES & TECH CORP (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190218268-A1 | AQUEOUSLY SOLUBLE & CHEMICALLY STABLE GLUCAGON PEPTIDES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2019-07-18 | — | — | US | disclosed |
| US-20190127433-A1 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | UNIV INDIANA RES & TECH CORP (US) | 2019-05-02 | — | — | US | disclosed |
| EP-3463424-A1 | GLUCAGON-LIKE PEPTIDE-1-T3 CONJUGATES | Indiana University Research & Technology Corporation (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3463415-A1 | AQUEOUSLY SOLUBLE & CHEMICALLY STABLE GLUCAGON PEPTIDES | Indiana University Research & Technology Corporation (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20110166062-A1 | GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2011075393-A2 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
| EP-2307037-A1 | GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS | Indiana University Research and Technology Corporation (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-2300037-A2 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | Indiana University Research and Technology Corporation (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2300035-A2 | GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY | Indiana University Research and Technology Corporation (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010148089-A1 | GIP RECEPTOR-ACTIVE GLUCAGON COMPOUNDS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010071807-A1 | AMIDE BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010011439-A2 | GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009155258-A2 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155257-A1 | GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY PHYSIOLOGICAL PH BUFFERS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290772-A1 | GLUCAGON-LIKE PEPTIDE-1-T3 CONJUGATES | GLP1R, GIPR, GCGR | ALDH1A1 2137/4885TSHR 4/4885TDP1 2747/4885 |
| US-20190127433-A1 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | GLP1R, GCGR, GIPR | ALDH1A1 4327/4885TSHR 35/4885TDP1 3721/4885 |
| US-10730923-B2 | Glucagon/GLP-1 receptor co-agonists | GLP1R, GCGR, GIPR | ALDH1A1 4327/4885TSHR 35/4885TDP1 3721/4885 |
| US-20190218268-A1 | AQUEOUSLY SOLUBLE & CHEMICALLY STABLE GLUCAGON PEPTIDES | IAPP, GLP1R, GCG | ALDH1A1 4040/4885TSHR 200/4885TDP1 3011/4885 |
| US-10696726-B2 | Insulin-incretin conjugates | GLP1R, IAPP, GIPR | ALDH1A1 3209/4885TSHR 152/4885TDP1 4546/4885 |
| US-20110166062-A1 | GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY | GIPR, GLP1R, GCGR | ALDH1A1 4437/4885TSHR 151/4885TDP1 4103/4885 |
| US-10683334-B2 | Aqueously soluble and chemically stable glucagon peptides | IAPP, GLP1R, GCG | ALDH1A1 4258/4885TSHR 102/4885TDP1 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.